OPKO Health, Inc. (OPK) stock
Close on Nov 17, 2026Market cap $1.21BP/E –Yield –
Earnings
OPKO Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of OPKO Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $65.40M | -56.9% | -$0.05 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 27, 2026after the close | $163.50M | +4.3% | -$0.01 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 28, 2026after the close | $124.20M | -17.1% | -$0.07 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $148.50M | -19.1% | -$0.04 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | $151.70M | -12.6% | $0.03 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025after the close | $156.80M | -13.9% | -$0.19 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 30, 2025after the close | $149.90M | -13.7% | -$0.10 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $183.60M | +0.9% | $0.01 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $173.60M | -2.8% | $0.03 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | $182.20M | -31.3% | -$0.01 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $173.70M | -26.9% | -$0.12 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $181.90M | -1.9% | -$0.09 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023after the close | $178.60M | -0.6% | -$0.11 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $265.40M | -14.4% | -$0.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023after the close | $237.60M | -27.8% | -$0.02 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023after the close | $185.40M | -53.8% | -$0.11 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $179.70M | -53.4% | -$0.11 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $309.90M | – | -$0.14 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022after the close | $329.20M | – | -$0.08 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $401.30M | – | -$0.11 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021after the close | $385.80M | – | $0.04 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 18, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
OPKO Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenue | Q4 FY2026 | $62.00M – $72.00M | – | New | Nov 4, 2026 |
| BARDA | Q4 FY2026 | $3.00M – $5.00M | – | Lowered | Nov 4, 2026 |
| Income/(loss) from discontinued operations | Q4 FY2026 | -$45.00M – -$35.00M | – | Lowered | Nov 4, 2026 |
| IP and other revenue | Q4 FY2026 | $21.00M – $27.00M | – | Lowered | Nov 4, 2026 |
| Pfizer gross profit share | Q4 FY2026 | $12.50M – $15.00M | – | Lowered | Nov 4, 2026 |
| Product revenue | Q4 FY2026 | $41.00M – $46.00M | – | New | Nov 4, 2026 |
| R&D included in costs and expenses | Q4 FY2026 | $32.00M – $35.00M | – | Lowered | Nov 4, 2026 |
| Total costs and expenses [from continuing operations] | Q4 FY2026 | $100.00M – $105.00M | – | Raised | Nov 4, 2026 |
| Services revenue | FY2026 | $296.00M – $306.00M | $300.00M – $312.00M | Raised | Jul 27, 2026 |
| Total revenue | FY2026 | $268.00M – $278.00M | – | New | Nov 4, 2026 |
| BARDA | FY2026 | $20.00M – $22.00M | – | Lowered | Nov 4, 2026 |
| Income/(loss) from discontinued operations | FY2026 | -$70.00M – -$60.00M | – | Lowered | Nov 4, 2026 |
| IP and other revenue | FY2026 | $105.00M – $110.00M | – | Lowered | Nov 4, 2026 |
| Pfizer gross profit share | FY2026 | $34.00M – $37.00M | – | Lowered | Nov 4, 2026 |
| Product revenue | FY2026 | $164.00M – $169.00M | – | New | Nov 4, 2026 |
| R&D included in costs and expenses | FY2026 | $125.00M – $130.00M | – | Lowered | Nov 4, 2026 |
| R&D included in costs and expenses | FY2026 | $125.00M – $135.00M | $125.00M – $135.00M | Lowered | Jul 27, 2026 |
| Total costs and expenses | FY2026 | $710.00M – $740.00M | $725.00M – $750.00M | Raised | Jul 27, 2026 |
| Total costs and expenses [from continuing operations] | FY2026 | $390.00M – $395.00M | – | Raised | Nov 4, 2026 |
Guidance vs results
The last range OPKO Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $73.00M – $78.00M | $65.40M | Below range |
| Q2 FY2026 | Revenue | $72.00M – $76.00M | $163.50M | Above range |
| Q1 FY2026 | Revenue | $15.00M – $20.00M | $124.20M | Above range |
Guidance history
Every forecast OPKO Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Product revenue | Q4 FY2026 | $41.00M – $46.00M | New |
| Nov 4, 2026 | IP and other revenue | Q4 FY2026 | $21.00M – $27.00M | Lowered |
| Nov 4, 2026 | Pfizer gross profit share | Q4 FY2026 | $12.50M – $15.00M | Lowered |
| Nov 4, 2026 | BARDA | Q4 FY2026 | $3.00M – $5.00M | Lowered |
| Nov 4, 2026 | Total costs and expenses [from continuing operations] | Q4 FY2026 | $100.00M – $105.00M | Raised |
| Nov 4, 2026 | R&D included in costs and expenses | Q4 FY2026 | $32.00M – $35.00M | Lowered |
| Nov 4, 2026 | Income/(loss) from discontinued operations | Q4 FY2026 | -$45.00M – -$35.00M | Lowered |
| Nov 4, 2026 | Product revenue | FY2026 | $164.00M – $169.00M | New |
| Nov 4, 2026 | IP and other revenue | FY2026 | $105.00M – $110.00M | Lowered |
| Nov 4, 2026 | Pfizer gross profit share | FY2026 | $34.00M – $37.00M | Lowered |
| Nov 4, 2026 | BARDA | FY2026 | $20.00M – $22.00M | Lowered |
| Nov 4, 2026 | Total costs and expenses [from continuing operations] | FY2026 | $390.00M – $395.00M | Raised |
| Nov 4, 2026 | R&D included in costs and expenses | FY2026 | $125.00M – $130.00M | Lowered |
| Nov 4, 2026 | Income/(loss) from discontinued operations | FY2026 | -$70.00M – -$60.00M | Lowered |
| Nov 4, 2026 | Total revenue | Q4 FY2026 | $62.00M – $72.00M | New |
| Nov 4, 2026 | Total revenue | FY2026 | $268.00M – $278.00M | New |
| Jul 27, 2026 | Total costs and expenses | FY2026 | $710.00M – $740.00M | Raised |
| Jul 27, 2026 | R&D included in costs and expenses | FY2026 | $125.00M – $135.00M | Lowered |
| Jul 27, 2026 | Total costs and expenses | Q3 FY2026 | $180.00M – $190.00M | New |
| Jul 27, 2026 | R&D included in costs and expenses | Q3 FY2026 | $34.00M – $38.00M | Lowered |
| Jul 27, 2026 | Services revenue | FY2026 | $296.00M – $306.00M | Raised |
| Jul 27, 2026 | Product revenue | FY2026 | $164.00M – $174.00M | Lowered |
| Jul 27, 2026 | IP and other revenue | FY2026 | $100.00M – $105.00M | Lowered |
| Jul 27, 2026 | Total revenue | FY2026 | $560.00M – $585.00M | Raised |
| Jul 27, 2026 | Pfizer gross profit share | FY2026 | $34.00M – $37.00M | Lowered |
| Jul 27, 2026 | BARDA | FY2026 | $18.00M – $22.00M | Lowered |
| Jul 27, 2026 | Services revenue | Q3 FY2026 | $73.00M – $78.00M | New |
| Jul 27, 2026 | Product revenue | Q3 FY2026 | $40.00M – $44.00M | Lowered |
| Jul 27, 2026 | IP and other revenue | Q3 FY2026 | $16.00M – $20.00M | Lowered |
| Jul 27, 2026 | Total revenue | Q3 FY2026 | $131.00M – $142.00M | Raised |
| Jul 27, 2026 | Pfizer gross profit share | Q3 FY2026 | $8.00M – $10.00M | Lowered |
| Jul 27, 2026 | BARDA | Q3 FY2026 | $5.00M – $7.00M | Lowered |
| Apr 28, 2026 | Pfizer gross profit share | Q2 FY2026 | $6.00M – $8.00M | New |
| Apr 28, 2026 | BARDA | Q2 FY2026 | $5.00M – $7.00M | Lowered |
| Apr 28, 2026 | Total costs and expenses | Q2 FY2026 | $180.00M – $190.00M | Raised |
| Apr 28, 2026 | R&D included in costs and expenses | Q2 FY2026 | $32.00M – $38.00M | Lowered |
| Apr 28, 2026 | Services revenue | Q2 FY2026 | $72.00M – $76.00M | New |
| Apr 28, 2026 | Product revenue | Q2 FY2026 | $38.00M – $42.00M | Lowered |
| Apr 28, 2026 | IP and other revenue | Q2 FY2026 | $15.00M – $19.00M | Lowered |
| Apr 28, 2026 | Total revenue | Q2 FY2026 | $127.00M – $132.00M | Raised |
| Feb 26, 2026 | R&D included in costs and expenses | Q1 FY2026 | $30.00M – $32.00M | Lowered |
| Feb 26, 2026 | Total costs and expenses | FY2026 | $725.00M – $750.00M | New |
| Feb 26, 2026 | R&D included in costs and expenses | FY2026 | $125.00M – $135.00M | Lowered |
| Feb 26, 2026 | Total costs and expenses | Q1 FY2026 | $170.00M – $180.00M | New |
| Feb 26, 2026 | IP and other revenue | Q1 FY2026 | $15.00M – $20.00M | Lowered |
| Feb 26, 2026 | Services revenue | FY2026 | $300.00M – $312.00M | New |
| Feb 26, 2026 | Product revenue | FY2026 | $160.00M – $170.00M | Lowered |
| Feb 26, 2026 | IP and other revenue | FY2026 | $70.00M – $80.00M | Lowered |
| Feb 26, 2026 | Total revenues | FY2026 | $530.00M – $560.00M | Raised |
| Feb 26, 2026 | Pfizer profit share | FY2026 | $34.00M – $37.00M | Lowered |
| Feb 26, 2026 | BARDA contract | FY2026 | $18.00M – $22.00M | Lowered |
| Feb 26, 2026 | Services revenue | Q1 FY2026 | $71.00M – $75.00M | New |
| Feb 26, 2026 | Product revenue | Q1 FY2026 | $38.00M – $45.00M | Lowered |
| Feb 26, 2026 | Total revenues | Q1 FY2026 | $125.00M – $140.00M | Raised |
| Feb 26, 2026 | Pfizer profit share | Q1 FY2026 | $5.00M – $6.00M | Lowered |
| Feb 26, 2026 | BARDA contract | Q1 FY2026 | $7.00M – $9.00M | Raised |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases OPKO Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Update
- Results
See a number that looks wrong?